Phase 3 Trial Results for Stempeutics Cell Therapy in Knee Osteoarthritis Published in American Journal of Sports Medicine (AJSM)
Mumbai: Alkem Laboratories on Saturday announced that a regulatory approval has been received from the Drug Controller General of India (DCGI) for the launch of StemOne in India. The product is indicated for the treatment of knee osteoarthritis. It is the first allogeneic cell therapy product to be approved for commercial use in India for Knee OA.
Stempeutics, a group company of Manipal Education and Medical Group (MEMG), has been granted the clearance from the Drugs Controller General of India (DCGI) for its stem cell product Stempeucel for conducting label extension phase 3 clinical trial in Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS).